Ingen Technologies, Inc. (IGNT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIngen Technologies, Inc. (IGNT) trades at $0.00001. Ingen Technologies, Inc. specializes in manufacturing medical devices for the respiratory industry, particularly for patients with chronic obstructive pulmonary disease (COPD). Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for IGNT: IGNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Ingen Technologies, Inc. (IGNT) Healthcare & Pipeline Overview
Ingen Technologies, Inc. manufactures and distributes respiratory medical devices, including oxygen flow meters and nasal cannulas, primarily serving patients with COPD. The company's focus on pneumatic metering devices and specialized nasal cannula technology positions it within a niche segment of the broader medical device market, characterized by increasing demand for home healthcare solutions.
What Is the Investment Thesis for IGNT?
Ingen Technologies, Inc. presents a focused investment opportunity within the respiratory medical device sector. The company's specialization in oxygen flow meters and nasal cannulas for COPD patients positions it to capitalize on the growing demand for home healthcare solutions. A key value driver is the company's proprietary Oxyview technology, which offers precise oxygen flow monitoring. However, potential investors may want to evaluate the company's negative P/E ratio of -0.05 and a significant negative profit margin of -7460.4%. While the gross margin is a high 95.7%, profitability remains a concern. Growth catalysts include expanding distribution networks and potential partnerships to reach a broader patient base. The investment thesis hinges on Ingen's ability to achieve profitability through increased sales volume and efficient cost management.
Based on FMP financials and quantitative analysis
IGNT Key Highlights
Ingen Technologies operates in the medical device industry, focusing on respiratory care products.
- The company's primary products include oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademarks.
- Ingen Technologies has a high gross margin of 95.7%, indicating efficient production processes.
- The company's P/E ratio is -0.05, reflecting current losses.
- Ingen Technologies serves patients suffering from chronic obstructive pulmonary disease (COPD).
Who Are IGNT's Competitors?
IGNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.81 | -0.07% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.20 | +2.37% | $5.70M | 30 5-pillar |
| SNWV SANUWAVE Health, Inc. | $5.54 | +6.54% | $47.6M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.94 | -1.01% | $48.4M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.59 | -6.02% | $54.4M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.51 | -2.84% | $80.0M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +0.20% | $107M | 34 5-pillar |
| INGN Inogen, Inc. | $5.80 | +0.61% | $157M | 36 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IGNT's Key Strengths?
Specialized product line focused on respiratory care.
- Proprietary Oxyview technology for accurate oxygen flow monitoring.
- Established presence in the respiratory medical device market.
- High gross margin of 95.7%.
What Are IGNT's Weaknesses?
Negative P/E ratio of -0.05, indicating current losses.
- High negative profit margin of -7460.4%.
- Limited product diversification.
- Dependence on the respiratory care market.
What Are the Key Risks for IGNT?
Competition from larger medical device manufacturers.
- Regulatory changes affecting the medical device industry.
- Economic downturn impacting healthcare spending.
- Technological advancements rendering existing products obsolete.
- The company's negative P/E ratio and high negative profit margin.
What Are IGNT's Competitive Advantages?
- Specialized product line focused on respiratory care.
- Proprietary Oxyview technology for accurate oxygen flow monitoring.
- Established presence in the respiratory medical device market.
- Brand recognition for Oxyview and Smart Nasal Cannula products.
What Does IGNT Do?
Founded in 1999 and based in Riverside, California, Ingen Technologies, Inc. operates as a medical device manufacturing company focused on the respiratory industry. The company develops, manufactures, and markets medical equipment designed for patients suffering from chronic obstructive pulmonary disease (COPD). Ingen's core product offerings include oxygen flow meters and nasal cannulas, marketed under the Oxyview and Smart Nasal Cannula trademarks. The Oxyview device is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient, ensuring accurate and reliable oxygen delivery. The Smart Nasal Cannula is designed to enhance patient comfort and improve oxygen delivery efficiency. Ingen Technologies targets the home healthcare market, providing solutions that enable patients to manage their respiratory conditions effectively outside of a hospital setting. The company's focus on specialized respiratory devices differentiates it from larger medical device manufacturers with broader product portfolios. Ingen Technologies distributes its products primarily within the United States.
What Products and Services Does IGNT Offer?
- Manufactures medical devices for the respiratory industry.
- Produces medical equipment for patients with chronic obstructive pulmonary disease (COPD).
- Offers oxygen flow meters under the Oxyview trademark.
- Provides nasal cannulas under the Smart Nasal Cannula trademark.
- Develops pneumatic metering devices to display and confirm oxygen flow rates.
- Focuses on improving oxygen delivery and patient comfort.
How Does IGNT Make Money?
- Manufactures and sells oxygen flow meters and nasal cannulas.
- Targets patients with chronic obstructive pulmonary disease (COPD).
- Distributes products through medical equipment suppliers and healthcare providers.
- Generates revenue from the sale of its medical devices.
What Industry Does IGNT Operate In?
Ingen Technologies operates within the medical device industry, specifically targeting the respiratory care segment. This segment is driven by the increasing prevalence of respiratory diseases such as COPD, and the growing demand for home healthcare solutions. The market is competitive, with established players like AFIB (Acutus Medical, Inc.) and ALST (Allstar Healthcare, Inc.) offering a range of respiratory devices. Ingen Technologies differentiates itself through its focus on specialized oxygen delivery and monitoring devices. The industry is subject to regulatory oversight, requiring companies to obtain approvals for their products. Market trends include the adoption of telehealth and remote patient monitoring, which could create opportunities for Ingen Technologies to integrate its devices with digital health platforms.
Who Are IGNT's Key Customers?
- Patients suffering from chronic obstructive pulmonary disease (COPD).
- Hospitals and clinics providing respiratory care.
- Home healthcare providers.
- Durable medical equipment (DME) suppliers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Ingen Technologies, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Riverside, US. IGNT has traded publicly since 1995.
Key Financial Metrics
Return on equity for Ingen Technologies, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Ingen Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Insider Activity
3 transactions · 2 purchases, 0 sales, 1 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
IGNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IGNT Latest News
No recent news available for IGNT.
IGNT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IGNT.
Price Targets
Wall Street price target analysis for IGNT.
IGNT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IGNT; grades run from A+ (80-100) to F (below 30).
Leadership: David S. Hanson
CEO
David S. Hanson is the Chief Executive Officer of Ingen Technologies, Inc. His background includes experience in the medical device industry, with a focus on product development and marketing. He has been involved in the development and commercialization of several respiratory care products. His expertise lies in identifying market needs and developing innovative solutions to address them. He has a strong understanding of the regulatory landscape and the challenges of bringing new medical devices to market.
Track Record: Under David S. Hanson's leadership, Ingen Technologies, Inc. has focused on expanding its product line and distribution network. Key milestones include the development and launch of the Smart Nasal Cannula and the expansion of the Oxyview product line. He has focused on improving the company's operational efficiency and reducing costs. However, the company's profitability remains a challenge.
IGNT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ingen Technologies, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet the requirements of higher tiers. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The Unknown disclosure status makes it difficult to assess the company's financial health.
- Low Liquidity: The OTC Other listing and small market cap suggest limited trading volume and wide bid-ask spreads.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight than exchange-listed companies.
- Going Concern Risk: Companies on the OTC Other tier may face financial difficulties or be at risk of bankruptcy.
- Price Volatility: Low trading volume can lead to significant price fluctuations.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and profitability trends.
- Check for any legal or regulatory issues involving the company.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company has been in operation since 1999.
- The company manufactures and sells medical devices.
- The company has trademarks for its Oxyview and Smart Nasal Cannula products.
- The company has a CEO, David S. Hanson.
- The company is based in the United States.
IGNT Healthcare Stock FAQ
What do analysts say about IGNT stock?
As of 2026-03-17, there is no available analyst coverage for Ingen Technologies, Inc. (IGNT). Given the company's OTC listing and small market capitalization, it is not widely followed by analysts. Key valuation metrics include a negative P/E ratio of -0.05 and a high gross margin of 95.7%.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the latest available information.
- OTC market data may be limited or unreliable.